Emerging Strategies for the Prevention and Treatment of Acute Graft-Versus-Host Disease
Originally presented at HOPA's 13th Annual Conference, March 2017.
This session will focus on updates in the prevention and treatment of GVHD. It will cover the rationale, clinical evidence, and outcomes of the most widely employed methods to prevent and treat GVHD as well as introduce novel approaches, including B- and T-cell targeted therapies, anticytokine therapy, and chemotaxis blockade.
- Review the epidemiology, risk factors, and clinical manifestations of acute and chronic graft-versus-host disease (GVHD).
- Elucidate the most common approaches to prevention and treatment of GVHD.
- Discuss emerging strategies for the prevention and treatment of GVHD.
Alex Ganetsky, PharmD BCOP
Alex Ganetsky is a board-certified hematology/oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania. He specializes in malignant hematology and hematopoietic cell transplantation. He earned his PharmD degree from Temple University in 2008 and subsequently completed a pharmacy practice residency at the University of North Carolina and a hematology/oncology specialty residency at Memorial Sloan Kettering Cancer Center. He has presented his work at national and international conferences and has published numerous articles in leading peer-reviewed journals. His primary research focus is related to identifying novel methods to mitigate complications of hematopoietic cell transplantation.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020